BridgeMD
New treatment option for Metastic Thyroid Cancer
Official title The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
ClinicalTrials.gov ID: NCT04927416
What this study is testing
What is 68-Gallium-DOTATATE-PET/CT?
68-Gallium-DOTATATE-PET/CT is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for metastic thyroid cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Background: About 5% to 10% of differentiated thyroid cancers become resistant to standard treatment with radioactive iodine. In these cases, treatment options are limited and generally not effective.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 3 months
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 98
You may be able to join if
- Data prospectively collected from the 28 people enrolled under this protocol, and data from 26 people collected under 77-DK-0096 and/or 00-CH-0093...
- Patients with HTC, DTC, and MTC will be identified by the investigators. The potential candidates for the study will be screened for eligibility to...
You likely can't join if
- were applied to the people who underwent imaging with the 68GADOTATATE PET/CT, either under the 77-DK-0096 sub-study or as clinically-indicated...
- Male or female, aged \>18 years.
- Patients with established thyroid cancer diagnosis presenting with either:
- Locally advanced or distant metastases, which are RAI-non-avid based on the or diagnostic or post-treatment whole body scan (WBS) OR --Patients with...
- Male or female, aged \>18 years.
- Patients with locally advanced or metastatic MTC or patients suspected of locally advanced or metastatic MTC with calcitonin level \> 500 pg/mL...
See the full eligibility criteria
- Data prospectively collected from the 28 people enrolled under this protocol, and data from 26 people collected under 77-DK-0096 and/or 00-CH-0093 will be analyzed. Among the 26 people prospectively evaluated under...
- Patients with HTC, DTC, and MTC will be identified by the investigators. The potential candidates for the study will be screened for eligibility to participate in the study and invited to sign the Research 68Ga-DOTATATE...
- were applied to the people who underwent imaging with the 68GADOTATATE PET/CT, either under the 77-DK-0096 sub-study or as clinically-indicated imaging under 00-CH-0093. In order to be eligible to participate in this...
- Male or female, aged \>18 years.
- Patients with established thyroid cancer diagnosis presenting with either:
- Locally advanced or distant metastases, which are RAI-non-avid based on the or diagnostic or post-treatment whole body scan (WBS) OR --Patients with RAI-non-responsive disease, who have the evidence of disease...
- Male or female, aged \>18 years.
- Patients with locally advanced or metastatic MTC or patients suspected of locally advanced or metastatic MTC with calcitonin level \> 500 pg/mL. EXCLUSION CRITERIA: people with either HTC, DTC, or MTC who meet any of...
- Pregnancy or lactation by self-report.
- Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma;
- Patients unable to give informed consent.
The study team makes the final eligibility decision.
Where it's taking place
- Bethesda, Maryland, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 3 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 98 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bethesda, Maryland, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.